Shares of Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) crossed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $11.22 and traded as high as $11.24. Innovent Biologics shares last traded at $11.24, with a volume of 1,139 shares changing hands.
Innovent Biologics Price Performance
The business’s fifty day simple moving average is $11.91 and its two-hundred day simple moving average is $11.23.
Innovent Biologics Company Profile
Innovent Biologics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. The company primarily targets oncology, autoimmune, cardiovascular and metabolic diseases, with an emphasis on biologic therapies, biosimilars and other specialty treatments. Its marketed and development portfolio includes therapies such as TYVYT (sintilimab), a PD-1 inhibitor developed in collaboration with Eli Lilly, as well as products based on or related to bevacizumab, rituximab and adalimumab.
Further Reading
- Five stocks we like better than Innovent Biologics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
